Central nervous system GVHD (CNS GVHD) is a rare entity and only 13 possible cases have been reported in the medical literature. 1, 2 We report the case of a 43-year-old man with a cauda equina syndrome that we believe is related to CNS GVHD.
Our patient was diagnosed with AML M1 and complete hematological remission was achieved with cytarabine and idarubicine followed by intermediate dose of cytarabine and amsacrine. Second consolidation was by an allogeneic hematopoietic stem cell transplantation from his HLAidentical sister. Conditioning consisted of CY and TBI. GVHD prophylaxis was with in vitro T-cell depletion with CAMPATH-1H followed by T-cell addback and cyclosporine (CsA). 3 Five months after hematopoietic stem cell transplantation, he presented with hematological and meningeal relapse (cerebrospinal fluid (CSF): 6 WBC/mm 3 , 80% of blasts), with an acute left brachial polyradiculopathy. Immunosuppression was withheld and rescue chemotherapy with FLAG-IDA (fludarabine, cytarabine, G-CSF, idarubicine) and five intrathecal (i.t.) injections of MTX, cytarabine and methylprednisolone were given. The neurological symptoms resolved rapidly after i.t. therapy and the blasts cleared from the CNS after two injections.
Six weeks later, the patient complained of a rapidly progressive motor and sensory deficit involving both the legs. He also noted perianal sensory loss and diminished sphincter control. Neurological examination showed a bilateral L1 sensory level below which all sensory modalities were found to be severely decreased, saddle anesthesia and incompetent anal and bladder sphincters. Hypotonia and bilateral lower limbs weakness (M3-4/5) more marked proximally and on the left, brisk reflexes, with the exception of an absent left patellar reflex, and a bilateral Babinski sign were also found. This resulted in complete paraparesis consistent with a high cauda equina lesion involving both the lower spinal cord and the lumbar and sacral roots. CSF was suggestive of an inflammatory cause with an increased total protein content (0.58 g/l) and 11 WBC/mm 3 (56% lymphocytes, 44% monocytes) but not a single blast cell by light microscopy or immunophenotyping. Viral PCRs (including herpes, CMV, BK and JC virus) of CSF were negative, as were direct examination and cultures for fungi and bacteria. Electroneuromyogram studies showed no distal abnormalities besides mild signs of chronic polyneuropathy. Brain and spinal magnetic resonance imaging were normal; in particular, there was no gadolinium enhancement of the conus or the cauda equina roots. Bone marrow biopsy showed complete remission, and full donor chimerism was obtained in blood and marrow. The patient was treated with high doses of methylprednisolone (1 g per day) for 5 days, starting 7 days after the onset of symptoms. I.t. chemotherapy was withheld but i.t. injections of steroids were continued (two injections of 40 mg methylprednisolone each, 5 days apart). The neurological symptoms improved and he progressively recovered sufficient muscular strength to walk independently. The sensory deficits regressed including the saddle anesthesia, and he regained near-normal sphincter control. He was considered neurologically intact 9 months after the beginning of his neurological problems.
Concurrent with the appearance of the neurological symptoms, biopsy-proven skin GVHD appeared. Systemic long-term steroid therapy (1 mg/kg) and CsA were withheld for 1 month to preserve the graft-versus-leukemia effect, but then had to be reintroduced to control progressive GVHD.
Before considering a diagnosis of CNS GVHD, several neurological entities, much more frequent after transplantation, must be ruled out. They are mainly related to metabolic encephalopathy, seizures, psychiatric symptoms, cerebral hemorrhage, infections, drug toxicity due to systemic or i.t. chemotherapy (with or without chemical arachnoiditis), 4 radiation toxicity or relapse of the neoplastic disease. [5] [6] [7] [8] In our patient, an infectious, neoplastic, paraneoplastic or mechanical origin was improbable, based on the CSF and magnetic resonance imaging findings. Toxicity due to systemic or i.t. chemotherapy was less probable due to the rapid and almost complete response to i.t. steroids. Chemical arachnoiditis was less probable due to the normal magnetic resonance imaging (in particular, no enhancement or thickening of the conus or the cauda equina roots). Because of the inflammatory aspect of the CSF, the concurrent skin GVHD, the rapid favorable outcome with i.t. methylprednisolone and full blood and bone marrow donor chimerism, we believed that neurological symptoms could be a manifestation of CNS GVHD.
Treatment of suspected CNS GVHD is, by analogy to GVHD in other organs, based on an immunosuppressive regimen. Descriptions in the literature report high-dose i.v. methylprednisolone regimens alone 1 or combined with CsA 2 or CY. 1 In one patient, tacrolimus was favored for its ability to cross the blood-brain barrier.
A diagnosis of probable CNS GVHD should ideally be histologically proven. On autopsy, two types of histological lesions have been found, parenchymal focal infiltration by lymphocytes (mainly CD3) 1,2 and angiitis of the CNS. 1 However, biopsy-proven cases are rare, and only three have been described while the patient was alive. 1, 2 In the absence of histological confirmation, only a presumptive diagnosis of CNS GVHD can be made based on exclusion of other pathologies, response to immunosuppressive therapy and presence of donor T cells in the CSF (not examined in our case).
Radiology examinations rarely seem to be helpful in diagnosing CNS GVHD: angiitis has been described on angiography in two patients 9, 10 and magnetic resonance imaging has shown, in some patients, nonspecific deep white matter changes 1 with only one description of a mass lesion. 2 No consensus exists on work-up and treatment options of this entity, and we agree with others 1 that continued reporting of similar cases will help to determine the clinical significance of possible CNS GVHD and possible treatment options. Interestingly, while all cases previously described involved brain structures, our case presented as an isolated, albeit dramatic, cauda equina syndrome with no clinical or neuroradiological evidence for cerebral abnormalities. Based on the exclusion of other diseases, the inflammatory state, clinical evaluation, laboratory results and response to immunosuppressive treatment, we attribute this cauda equina syndrome to probable GVHD. This case is significant because it is the first description of cauda equina syndrome due to probable GVHD and the first where a trial of intrathecal steroid therapy was successful. 
